<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="886">
  <stage>Registered</stage>
  <submitdate>18/11/2005</submitdate>
  <approvaldate>18/11/2005</approvaldate>
  <actrnumber>ACTRN12605000756628</actrnumber>
  <trial_identification>
    <studytitle>Continued use of Atorvostatin in sepsis</studytitle>
    <scientifictitle>A phase II randomised controlled trial in patients on statin therapy who develop sepsis to evaluate the effect of continued atorvastatin use  on the incidence of severe sepsis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis / infection in patients taking statin therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Atorvostatin as continuation of statin therapy for a 28 day study period ( or until discharge form hospital)</interventions>
    <comparator>Placebo as continuation of statin therapy for a 28 day study period ( or until discharge form hospital).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of severe sepsis</outcome>
      <timepoint>during hospital admission</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>28 Day mortality</outcome>
      <timepoint>post hospital admission date</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biological markers of inflammation , lipid profile , oxidative stress.</outcome>
      <timepoint>during hospital admission</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients with sepsis syndrome who are on statin therapy at the time of admisison to hospital are eligable for inclusion.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, acute liver failure or chronic liver disease ( more than Childs B), patients who are moribund and not expected to survive 24 hrs, patients with rhabdomyolysis or myopathy of any cause. Patients in whom any enteral intake will clearly not be possible within 72 hours.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>computer generated random list</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/05/2006</anticipatedstartdate>
    <actualstartdate>8/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>17/10/2008</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Peter Kruger, Intensive Care Specialist,  Princess Alexandra Hospital, Brisbane</primarysponsorname>
    <primarysponsoraddress>Princess Alexandra hospital, Brisbane, Queensland, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australian and New Zealand College of Anaesthetists</fundingname>
      <fundingaddress>630 St kilda Road, Melbourne,Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NIL</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>study completed and the results are now published in the American journal of Respiratory and critical care medicine</summary>
    <trialwebsite />
    <publication>The results of the study have been published : Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B. Continuation of statin therapy in patients with presumed infection: A randomised controlled trial. Am J Respir Crit Care Med 2011;183(6):774-781.

they were presented in part at several meetings including:

8th world congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany, March 2010. Topic: Statins in sepsis: the first clinical results. 

23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Berlin, Germany. April 2013, Possible mechanisms of action for statins in infection.

International Symposium on Intensive Care and Emergency Medicine, Brussels , March, 2012 and 2011   -Statins in Sepsis, 

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital  HREC</ethicname>
      <ethicaddress>Princess Alexandra Hospital
Brisbane, Australia</ethicaddress>
      <ethicapprovaldate>16/12/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>16/11/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Dr Peter Kruger</name>
      <address>Intensive Care Unit
Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 32402111</phone>
      <fax>+61 7 32407074</fax>
      <email>peter_kruger@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Dr Peter Kruger</name>
      <address>Intensive Care Unit
Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 32402111</phone>
      <fax>+61 7 32407074</fax>
      <email>peter_kruger@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>peter kruger</name>
      <address>Princess ALexandra Hospital</address>
      <phone>+61 7 3176 2111</phone>
      <fax />
      <email>peter.kruger@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>